Abstract:Topic: 22. Stem cell transplantation - Clinical Background: As a rare but life-threatening critical complication following allogenic haematopoietic stem cell transplantation (allo-HSCT), liver failure is significantly related to poor survival and increased non-relapse mortality. Therefore, identifying patients at high risk of death who should receive specific therapeutic management is key to improving their survival. Here, we established the first clinical prognostic model to predict post-transplant liver failure prognosis to facilitate physician decision-making. Aims: This study was aimed at establishing a prognostic model for selecting post-transplant patients who are at a higher risk of liver failure and disease mortality. Methods: We retrospectively evaluated 113 consecutive liver failure patients who underwent allo-HSCT at a single centre between 2010 and 2022. These patients were further randomly divided into a derivation cohort of 57 patients and a validation cohort of 56 patients. Pearson’s chi-square test and Fisher’s exact test were applied to compare the categorical variables. Outcomes described by the cumulative incidence of overall survival (OS), non-relapse mortality (NRM) and relapse were evaluated by Kaplan-Meier method and the log-rank test. We assessed the prognostic model performance by evaluating the discrimination [area under the curve (AUC)], calibration (calibration plot), and net benefit [decision curve analysis (DCA)]. Results: In total, 113 of 16819 patients (0.67%) were diagnosed with liver failure after transplantation. Disseminated intravascular coagulation (DIC), viral hepatitis, acute kidney injury (AKI), gastrointestinal disease or bleeding, poor platelet implantation, and chronic graft versus host disease (cGHVD) were determined to be significant risk factors for the occurrence of liver failure after allo-HSCT. Because of the higher mortality rate after liver failure, these factors are also significantly related to mortality in patients with liver failure after allo-HSCT. The AUCs of the model were 0.887 (95% CI 0.833-0.940) and 0.770 (0.701-0.839) for the training and validation cohorts, respectively. The calibration plots showed high consistency between the predicted and observed outcomes. Patients were further classified into low-risk and high-risk categories while considering the observed death distribution of the total cohort by tertiles of 2-year outcome probability according to the score. Significant differences in Kaplan-Meier estimations of overall survival were obtained. Summary/Conclusion: The predictive models developed for the occurrence and mortality of liver failure performed well in terms of discrimination, and they might assist clinicians with personalized strategies for liver failure prevention and treatment in patients after allo-HSCT. Keywords: Liver, Allogeneic hematopoietic stem cell transplant, Prognostic factor

A Murine Model of Hepatic Veno-occlusive Disease Induced by Allogeneic Hematopoietic Stem Cell Transplantation

Clinical and pathologic study on hepatic veno-occlusive disease

Early Endothelial Activation in a Mouse Model of Graft vs Host Disease Following Chemotherapy

A New Murine Model of Chronic Graft Versus Host Disease

The protective effects of umbilical cord‐derived endothelial colony forming cells on hepatic veno‐occlusive disease

Improvement of mesenchymal stromal cells and their derivatives for treating acute liver failure

Establishment of a Murine Model of Chronic Graft-Versus-Host Disease after Minor Histocompatibility Antigen Mismatched Bone Marrow Transplantation

Improvement of Liver Transplantation Outcome by Heme Oxygenase-1-Transduced Bone Marrow Mesenchymal Stem Cells in Rats

A Murine Model of Mixed Bone Marrow Transplant:Importance of the Splenocytes to Balance HVG and GVH Reactions

HBV Infection-Induced Liver Cirrhosis Development in Dual-Humanised Mice with Human Bone Mesenchymal Stem Cell Transplantation

Establishment of a Nonmyeloablative Allogeneic Peripheral Blood Stem Cell Transplantation Model in Mice and Its Related Study

PB2409: CLINICAL PROGNOSTIC MODEL OF LIVER FAILURE AFTER ALLOGENEIC HAEMATOPOIETIC STEM CELL TRANSPLANTATION

[Efficiency of Prevention and Treatment of Veno-Occlusive Disease of the Liver after Allogeneic Stem Cell Transplantation].

[A Clinical Analysis of Hepatic Veno-Occlusive Disease after Hematopoietic Stem Cell Transplantation].

Role of Multiparametric Ultrasound in Evaluating Hepatic Acute Graft-versus-Host Disease: an Animal Study

Charcoal hemofiltration for hepatic veno-occlusive disease after hematopoietic stem cell transplantation

Progress in the Diagnosis and Treatment of Veno-Occlusive Disease/Sinusoidal Obstruction Syndrome After Allogeneic Hematopoietic Stem Cell Transplantation

RETRACTED ARTICLE: Heme Oxygenase-1-modified Bone Marrow Mesenchymal Stem Cells Combined with Normothermic Machine Perfusion to Protect Donation after Circulatory Death Liver Grafts

Posttransplant Hemophagocytic Lymphohistiocytosis Driven by Myeloid Cytokines and Vicious Cycles of T-Cell and Macrophage Activation in Humanized Mice

Heme Oxygenase-1-Modified Bone Marrow Mesenchymal Stem Cells Perfusion Using a Normothermic Machine Perfusion System Reduces the Acute Rejection of Liver Transplantation by Regulating Natural Killer T Cell Co-Inhibitory Receptors

Relationship Between Graft-Versus-host Disease and Endothelium Injury Following Hematopoietic Stem Cells Transplantation in Mice